No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
No Data
Investors in Codexis (NASDAQ:CDXS) Have Unfortunately Lost 88% Over the Last Three Years
Syntis Bio Launches to Revolutionize Oral Therapy for Obesity, Diabetes and Rare Diseases by Unlocking the Full Therapeutic Potential of the Small Intestine
Codexis Initiated at Overweight by Cantor Fitzgerald
Cantor Fitzgerald Starts Codexis With Overweight Rating, $11 Price Target
Codexis to Participate in Jefferies Global Healthcare Conference
Codexis to Participate in TD Cowen 2nd Annual Sustainability Week